Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Emerging threat of triazole-resistant Aspergillus fumigatus.

Rybak JM, Fortwendel JR, Rogers PD.

J Antimicrob Chemother. 2018 Dec 17. doi: 10.1093/jac/dky517. [Epub ahead of print]

PMID:
30561652
2.

A Hyperactive Form of the Zinc Cluster Transcription Factor Stb5 Causes YOR1 Overexpression and Beauvericin Resistance in Candida albicans.

Ramírez-Zavala B, Manz H, Englert F, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01655-18. doi: 10.1128/AAC.01655-18. Print 2018 Dec.

PMID:
30249688
3.

Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata.

Whaley SG, Zhang Q, Caudle KE, Rogers PD.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01070-18. doi: 10.1128/AAC.01070-18. Print 2018 Oct.

PMID:
30038038
4.

Loss of Upc2p-Inducible ERG3 Transcription Is Sufficient To Confer Niche-Specific Azole Resistance without Compromising Candida albicans Pathogenicity.

Luna-Tapia A, Willems HME, Parker JE, Tournu H, Barker KS, Nishimoto AT, Rogers PD, Kelly SL, Peters BM, Palmer GE.

MBio. 2018 May 22;9(3). pii: e00225-18. doi: 10.1128/mBio.00225-18.

5.

Jjj1 Is a Negative Regulator of Pdr1-Mediated Fluconazole Resistance in Candida glabrata.

Whaley SG, Caudle KE, Simonicova L, Zhang Q, Moye-Rowley WS, Rogers PD.

mSphere. 2018 Feb 21;3(1). pii: e00466-17. doi: 10.1128/mSphere.00466-17. eCollection 2018 Jan-Feb.

6.

Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Rybak JM, Dickens CM, Parker JE, Caudle KE, Manigaba K, Whaley SG, Nishimoto AT, Luna-Tapia A, Roy S, Zhang Q, Barker KS, Palmer GE, Sutter TR, Homayouni R, Wiederhold NP, Kelly SL, Rogers PD.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00651-17. doi: 10.1128/AAC.00651-17. Print 2017 Sep.

7.

Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains.

Popp C, Hampe IAI, Hertlein T, Ohlsen K, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00584-17. doi: 10.1128/AAC.00584-17. Print 2017 Jul.

8.

An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis.

Peters BM, Luna-Tapia A, Tournu H, Rybak JM, Rogers PD, Palmer GE.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00084-17. doi: 10.1128/AAC.00084-17. Print 2017 Jun.

9.

Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.

Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD.

Front Microbiol. 2017 Jan 12;7:2173. doi: 10.3389/fmicb.2016.02173. eCollection 2016. Review.

10.

Azole Resistance in Candida glabrata.

Whaley SG, Rogers PD.

Curr Infect Dis Rep. 2016 Dec;18(12):41. Review.

PMID:
27761779
11.

The RTA3 Gene, Encoding a Putative Lipid Translocase, Influences the Susceptibility of Candida albicans to Fluconazole.

Whaley SG, Tsao S, Weber S, Zhang Q, Barker KS, Raymond M, Rogers PD.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6060-6. doi: 10.1128/AAC.00732-16. Print 2016 Oct.

12.

Antifungal adjuvants: Preserving and extending the antifungal arsenal.

Butts A, Palmer GE, Rogers PD.

Virulence. 2017 Feb 17;8(2):198-210. doi: 10.1080/21505594.2016.1216283. Epub 2016 Jul 26. Review.

13.

A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens.

Daniels CC, Rogers PD, Shelton CM.

J Pediatr Pharmacol Ther. 2016 Jan-Feb;21(1):27-35. doi: 10.5863/1551-6776-21.1.27. Review.

14.

Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.

Rybak JM, Marx KR, Nishimoto AT, Rogers PD.

Pharmacotherapy. 2015 Nov;35(11):1037-51. doi: 10.1002/phar.1652. Epub 2015 Nov 2. Review.

PMID:
26598096
15.

Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in Candida parapsilosis.

Berkow EL, Manigaba K, Parker JE, Barker KS, Kelly SL, Rogers PD.

Antimicrob Agents Chemother. 2015 Oct;59(10):5942-50. doi: 10.1128/AAC.01358-15. Epub 2015 Jul 13.

16.

Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans.

Flowers SA, Colón B, Whaley SG, Schuler MA, Rogers PD.

Antimicrob Agents Chemother. 2015 Jan;59(1):450-60. doi: 10.1128/AAC.03470-14. Epub 2014 Nov 10.

17.

Mechanisms of Antifungal Drug Resistance.

Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS.

Cold Spring Harb Perspect Med. 2014 Nov 10;5(7):a019752. doi: 10.1101/cshperspect.a019752. Review.

18.

Mutational analysis of essential septins reveals a role for septin-mediated signaling in filamentation.

Blankenship JR, Cheng S, Woolford CA, Xu W, Johnson TM, Rogers PD, Fanning S, Nguyen MH, Clancy CJ, Mitchell AP.

Eukaryot Cell. 2014 Nov;13(11):1403-10. doi: 10.1128/EC.00127-14. Epub 2014 Sep 12.

19.

Disruption of the transcriptional regulator Cas5 results in enhanced killing of Candida albicans by Fluconazole.

Vasicek EM, Berkow EL, Bruno VM, Mitchell AP, Wiederhold NP, Barker KS, Rogers PD.

Antimicrob Agents Chemother. 2014 Nov;58(11):6807-18. doi: 10.1128/AAC.00064-14. Epub 2014 Sep 2.

20.

SAGA/ADA complex subunit Ada2 is required for Cap1- but not Mrr1-mediated upregulation of the Candida albicans multidrug efflux pump MDR1.

Ramírez-Zavala B, Mogavero S, Schöller E, Sasse C, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2014 Sep;58(9):5102-10. doi: 10.1128/AAC.03065-14. Epub 2014 Jun 16.

21.

UPC2A is required for high-level azole antifungal resistance in Candida glabrata.

Whaley SG, Caudle KE, Vermitsky JP, Chadwick SG, Toner G, Barker KS, Gygax SE, Rogers PD.

Antimicrob Agents Chemother. 2014 Aug;58(8):4543-54. doi: 10.1128/AAC.02217-13. Epub 2014 May 27.

22.

UPC2 is universally essential for azole antifungal resistance in Candida albicans.

Vasicek EM, Berkow EL, Flowers SA, Barker KS, Rogers PD.

Eukaryot Cell. 2014 Jul;13(7):933-46. doi: 10.1128/EC.00221-13. Epub 2014 Mar 21.

23.

Mitochondrial two-component signaling systems in Candida albicans.

Mavrianos J, Berkow EL, Desai C, Pandey A, Batish M, Rabadi MJ, Barker KS, Pain D, Rogers PD, Eugenin EA, Chauhan N.

Eukaryot Cell. 2013 Jun;12(6):913-22. doi: 10.1128/EC.00048-13. Epub 2013 Apr 12.

24.

Synchrotron radiation-based far-infrared spectroscopic ellipsometer with full Mueller-matrix capability.

Stanislavchuk TN, Kang TD, Rogers PD, Standard EC, Basistyy R, Kotelyanskii AM, Nita G, Zhou T, Carr GL, Kotelyanskii M, Sirenko AA.

Rev Sci Instrum. 2013 Feb;84(2):023901. doi: 10.1063/1.4789495.

PMID:
23464221
25.

Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans.

Flowers SA, Barker KS, Berkow EL, Toner G, Chadwick SG, Gygax SE, Morschhäuser J, Rogers PD.

Eukaryot Cell. 2012 Oct;11(10):1289-99. doi: 10.1128/EC.00215-12. Epub 2012 Aug 24.

26.

Role of a Candida albicans Nrm1/Whi5 homologue in cell cycle gene expression and DNA replication stress response.

Ofir A, Hofmann K, Weindling E, Gildor T, Barker KS, Rogers PD, Kornitzer D.

Mol Microbiol. 2012 May;84(4):778-94. doi: 10.1111/j.1365-2958.2012.08056.x. Epub 2012 Apr 16.

27.

Echinocandin use in the neonatal intensive care unit.

Caudle KE, Inger AG, Butler DR, Rogers PD.

Ann Pharmacother. 2012 Jan;46(1):108-16. doi: 10.1345/aph.1Q346. Epub 2011 Dec 20. Review.

PMID:
22190252
28.

The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans.

Sasse C, Schillig R, Dierolf F, Weyler M, Schneider S, Mogavero S, Rogers PD, Morschhäuser J.

PLoS One. 2011;6(9):e25623. doi: 10.1371/journal.pone.0025623. Epub 2011 Sep 27.

29.

Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1.

Schubert S, Popp C, Rogers PD, Morschhäuser J.

Eukaryot Cell. 2011 Aug;10(8):1110-21. doi: 10.1128/EC.05100-11. Epub 2011 Jun 17.

30.

Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans.

Schubert S, Barker KS, Znaidi S, Schneider S, Dierolf F, Dunkel N, Aïd M, Boucher G, Rogers PD, Raymond M, Morschhäuser J.

Antimicrob Agents Chemother. 2011 May;55(5):2212-23. doi: 10.1128/AAC.01343-10. Epub 2011 Mar 14.

31.

Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1.

Mogavero S, Tavanti A, Senesi S, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2011 May;55(5):2061-6. doi: 10.1128/AAC.01467-10. Epub 2011 Feb 22.

32.

Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon.

Caudle KE, Barker KS, Wiederhold NP, Xu L, Homayouni R, Rogers PD.

Eukaryot Cell. 2011 Mar;10(3):373-83. doi: 10.1128/EC.00073-10. Epub 2010 Dec 30.

33.

Antimicrobial peptide MUC7 12-mer activates the calcium/calcineurin pathway in Candida albicans.

Lis M, Liu TT, Barker KS, Rogers PD, Bobek LA.

FEMS Yeast Res. 2010 Aug 1;10(5):579-86. doi: 10.1111/j.1567-1364.2010.00638.x. Epub 2010 May 29.

34.

Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents.

Hoehamer CF, Cummings ED, Hilliard GM, Rogers PD.

Antimicrob Agents Chemother. 2010 May;54(5):1655-64. doi: 10.1128/AAC.00756-09. Epub 2010 Feb 9.

35.

Fluconazole prophylaxis in high-risk neonates.

Reed BN, Caudle KE, Rogers PD.

Ann Pharmacother. 2010 Jan;44(1):178-84. doi: 10.1345/aph.1M364. Epub 2009 Dec 29. Review.

PMID:
20040701
36.

An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans.

Heilmann CJ, Schneider S, Barker KS, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2010 Jan;54(1):353-9. doi: 10.1128/AAC.01102-09. Epub 2009 Nov 2.

37.

Computer simulation to aid the risk assessment of wheelchair and special seating systems used in transport.

Rogers PD, Gibson C, Wilcox SJ, Chong A.

J Med Eng Technol. 2009;33(8):642-9. doi: 10.3109/03091900903151004.

PMID:
19848858
38.

The role of voriconazole in the treatment of central nervous system blastomycosis.

Ta M, Flowers SA, Rogers PD.

Ann Pharmacother. 2009 Oct;43(10):1696-700. doi: 10.1345/aph.1M010. Epub 2009 Sep 1. Review.

PMID:
19724015
39.

Proteomic analysis of Mrr1p- and Tac1p-associated differential protein expression in azole-resistant clinical isolates of Candida albicans.

Hoehamer CF, Cummings ED, Hilliard GM, Morschhäuser J, Rogers PD.

Proteomics Clin Appl. 2009 Aug;3(8):968-78. doi: 10.1002/prca.200800252.

40.

The nonmedical use of prescription drugs by adolescents.

Rogers PD, Copley L.

Adolesc Med State Art Rev. 2009 Apr;20(1):1-8, vii. Review.

PMID:
19492687
41.

Identification of the Candida albicans Cap1p regulon.

Znaidi S, Barker KS, Weber S, Alarco AM, Liu TT, Boucher G, Rogers PD, Raymond M.

Eukaryot Cell. 2009 Jun;8(6):806-20. doi: 10.1128/EC.00002-09. Epub 2009 Apr 24.

42.

Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.

Löwenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R, Bond S, Kremers W, Nichols T, Krain B, Reimer K.

Expert Opin Pharmacother. 2009 Mar;10(4):531-43. doi: 10.1517/14656560902796798 .

PMID:
19243306
43.

Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains.

Schubert S, Rogers PD, Morschhäuser J.

Antimicrob Agents Chemother. 2008 Dec;52(12):4274-80. doi: 10.1128/AAC.00740-08. Epub 2008 Sep 22.

44.

Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains.

Dunkel N, Blass J, Rogers PD, Morschhäuser J.

Mol Microbiol. 2008 Aug;69(4):827-40. doi: 10.1111/j.1365-2958.2008.06309.x. Epub 2008 May 27.

45.

Transcriptome profile of the vascular endothelial cell response to Candida albicans.

Barker KS, Park H, Phan QT, Xu L, Homayouni R, Rogers PD, Filler SG.

J Infect Dis. 2008 Jul 15;198(2):193-202. doi: 10.1086/589516.

PMID:
18500935
46.

A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate.

Dunkel N, Liu TT, Barker KS, Homayouni R, Morschhäuser J, Rogers PD.

Eukaryot Cell. 2008 Jul;7(7):1180-90. doi: 10.1128/EC.00103-08. Epub 2008 May 16.

47.

Increases in SLT2 expression and chitin content are associated with incomplete killing of Candida glabrata by caspofungin.

Cota JM, Grabinski JL, Talbert RL, Burgess DS, Rogers PD, Edlind TD, Wiederhold NP.

Antimicrob Agents Chemother. 2008 Mar;52(3):1144-6. Epub 2007 Dec 17.

48.

The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans.

Morschhäuser J, Barker KS, Liu TT, BlaB-Warmuth J, Homayouni R, Rogers PD.

PLoS Pathog. 2007 Nov;3(11):e164.

49.

Genome-wide expression and location analyses of the Candida albicans Tac1p regulon.

Liu TT, Znaidi S, Barker KS, Xu L, Homayouni R, Saidane S, Morschhäuser J, Nantel A, Raymond M, Rogers PD.

Eukaryot Cell. 2007 Nov;6(11):2122-38. Epub 2007 Sep 28.

50.

Creatine and other supplements.

Lattavo A, Kopperud A, Rogers PD.

Pediatr Clin North Am. 2007 Aug;54(4):735-60, xi. Review.

PMID:
17723874

Supplemental Content

Loading ...
Support Center